BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31712777)

  • 1. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.
    Merz M; Hielscher T; Schult D; Mai EK; Raab MS; Hillengass J; Seckinger A; Hose D; Granzow M; Jauch A; Goldschmidt H
    Leukemia; 2020 Apr; 34(4):1192-1196. PubMed ID: 31712777
    [No Abstract]   [Full Text] [Related]  

  • 2. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
    Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
    Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretation of cytogenetic results in multiple myeloma for clinical practice.
    Rajan AM; Rajkumar SV
    Blood Cancer J; 2015 Oct; 5(10):e365. PubMed ID: 26517360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic patterns of progression in smoldering multiple myeloma.
    Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
    Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytogenetic analysis (chromosome analysis and FISH analysis)].
    Wakui K
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():162-6. PubMed ID: 16416788
    [No Abstract]   [Full Text] [Related]  

  • 6. Do we need cytogenetics in the follow-up of multiple myeloma?
    Gay F; Goldschmidt H
    Br J Haematol; 2019 May; 185(3):399-401. PubMed ID: 30706441
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
    Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
    Oben B; Froyen G; Maclachlan KH; Leongamornlert D; Abascal F; Zheng-Lin B; Yellapantula V; Derkach A; Geerdens E; Diamond BT; Arijs I; Maes B; Vanhees K; Hultcrantz M; Manasanch EE; Kazandjian D; Lesokhin A; Dogan A; Zhang Y; Mikulasova A; Walker B; Morgan G; Campbell PJ; Landgren O; Rummens JL; Bolli N; Maura F
    Nat Commun; 2021 Mar; 12(1):1861. PubMed ID: 33767199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
    Lussier T; Schoebe N; Mai S
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cytogenetic analysis of telomere rearrangements.
    Lese CM; Ledbetter DH
    Curr Protoc Hum Genet; 2001 May; Chapter 8():Unit 8.11. PubMed ID: 18428312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
    Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
    Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
    Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eruptive ulcerative follicular spicules heralding progression of smoldering multiple myeloma.
    Tomasini C; Michelerio A; Brazzelli V
    J Cutan Pathol; 2019 Nov; 46(11):844-851. PubMed ID: 31161673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard.
    Fonseca R; Gonzalez-Velez M
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32207672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of treatment of smoldering myeloma: delay until progression.
    Kumar SK
    Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of cytogenetics in the prognosis of patients with multiple myeloma].
    Paluszewska M; Dwilewicz-Trojaczek J; Stańczak H; Brycz-Witkowska J; Chmarzyńska-Mróz E; Rokicka M; Torosian T; Wasiutyński A; Jedrzejczak WW
    Pol Arch Med Wewn; 2003 Sep; 110(3):973-9. PubMed ID: 14699690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
    Muchtar E; Kumar SK; Magen H; Gertz MA
    Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
    Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.